Value of early post-operative growth hormone testing in predicting long-term remission and residual disease after transsphenoidal surgery for acromegaly
Authors
Wang, Y. Y.Waqar, M.
Abou-Zeid, A.
Kearney, T.
Caputo, C.
Davis, J.
Trainer, Peter J
Higham, Claire E
Roncaroli, F.
Gnanalingham, K. K.
Affiliation
Departments of Neurosurgery, Greater Manchester Neurosciences Centre, Salford Royal Foundation Trust (SRFT),Issue Date
2021
Metadata
Show full item recordAbstract
Introduction: Surgical remission for acromegaly is dependent on a number of factors including tumour size, invasiveness, and surgical expertise. We studied the value of early post-operative growth hormone (GH) level as a predictor of outcome and to guide early surgical re-exploration for residual disease in patients with acromegaly. Methods: Patients with acromegaly undergoing first-time endoscopic transsphenoidal surgery between 2005 and 2015, in 2 regional neurosurgical centres, were studied. Insulin-like growth factor-1 (IGF-1), basal GH (i.e., sample before oral glucose), and GH nadir on oral glucose tolerance test (OGTT) were tested at various time points, including 2�5 days post-operatively. Definition of disease remission was according to the 2010 consensus statement (i.e., GH nadir <0.4 ?g/L during an OGTT and normalized population-matched IGF-1). Forward stepwise logistic regression was used to determine factors associated with remission. Results: We investigated 81 consecutive patients with acromegaly, 67 (83%) of which had macroadenomas and 22 (27%) were noted to be invasive at surgery. Mean follow-up was 44 � 25 months. Overall, surgical remission was achieved in 55 (68%) patients at final follow-up. On univariate analysis, the remission rates at the end of the study period for patients with early post-operative GH nadir on OGTT of <0.4 (N = 43), between 0.4 and 1 (N = 28), and >1 ?g/L (N = 8) were 88, 54, and 20%, respectively. Similar results were seen with basal GH on early post-operative OGTT. On multivariate regression analysis, pre-operative IGF-1 (odds ratio of 13.1) and early post-operative basal GH (odds ratio of 5.0) and GH nadir on OGTT (odds ratio of 6.8) were significant predictors of residual disease. Based on a raised early GH nadir and post-operative MR findings, 10 patients underwent early surgical re-exploration. There was reduction in post-operative GH levels in 9 cases, of which 5 (50%) achieved long-term remission. There was an increased risk of new pituitary hormone deficiencies in patients having surgical re-exploration compared to those having a single operation (60 vs. 14%). Conclusions: An early post-operative basal GH and GH nadir on OGTT are reliable predictors of long-term disease remission. It can be used to guide patients for early surgical re-exploration for residual disease, although there is increased risk of hypopituitarism.Citation
Wang YY, Waqar M, Abou-Zeid A, Kearney T, Caputo C, Davis J, et al. Value of early post-operative growth hormone testing in predicting long-term remission and residual disease after transsphenoidal surgery for Acromegaly. Neuroendocrinology. S. Karger AG; 2021.Journal
NeuroendocrinologyDOI
10.1159/000517476PubMed ID
34052822Additional Links
https://dx.doi.org/10.1159/000517476Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1159/000517476
Scopus Count
Collections
Related articles
- 2010 versus the 2000 consensus criteria in patients with normalised insulin-like growth factor 1 after transsphenoidal surgery has high predictive values for long-term recurrence-free survival in acromegaly.
- Authors: Shen M, Chen Z, Shou X, He W, Qiao N, Ma Z, Ye Z, Zhang Y, Zhang Q, Zhou X, Cao X, Zhang Z, Ye H, Li Y, Zhao Y, Li S, He M, Wang Y
- Issue date: 2021 May
- Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test.
- Authors: Sakata K, Nagata Y, Takeshige N, Kikuchi J, Shikata M, Ashida K, Nomura M, Morioka M
- Issue date: 2021 Sep
- Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
- Authors: Serri O, Beauregard C, Hardy J
- Issue date: 2004 Feb
- Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.
- Authors: Wang YY, Higham C, Kearney T, Davis JR, Trainer P, Gnanalingham KK
- Issue date: 2012 Mar
- Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
- Authors: Cardinal T, Rutkowski MJ, Micko A, Shiroishi M, Jason Liu CS, Wrobel B, Carmichael J, Zada G
- Issue date: 2020 Jun